Published data indicate that the HER2/HER3 signaling pathways play an important role both in NSCLC tumors resistant to inhibitors of EGFR (cetuximab and erlotinib) 78-81 and in NSCLC cancers driven by activating mutations in HER2 (4% of NCSLC patients) 82. Here, ERBB2 is linked to non-small cell lung carcinoma.